Figure 1. Structures of KRN7000 (1), OCH (2) and α-C-GalCer (3)
Engagement of the CD1d-α-GalCer complex by the TCR of iNKT cells results in a rapid production of Th1 and Th2 cytokines both by iNKT cells itself and by activation of bystander immune cells. 8 The robust cytokine production shows promise for a broad range of therapeutic applications, but despite its potent immune response α-GalCer showed limited therapeutic outcome in the clinic. 9, 10 The concomitant release of both Th1 and Th2 cytokines, which have opposing effects in vivo, is believed to account for its poor efficacy. Indeed, α-GalCer analogues capable of skewing the cytokine profile have improved therapeutic potential. 11, 12, 13 OCH (2), characterized by a truncated phytosphingosine chain, improves disease in animal models of experimental autoimmune encephalitis and arthritis as a result of a Th2 biased cytokine secretion. 14, 15 Stabilizing the anomeric bond by substituting a methylene unit for the glycosidic oxygen gave rise to α-C-GalCer (3), a compound with a marked Th1 response and superior malaria protection in mice. 16 Modifications of the galactose moiety are mostly focusing on the 6"-position, 17, 18 as other alterations generally result in poor antigenicity. Previously, we discovered that a C-6"-naphthylurea derivative (NU-α-GalCer, 4, Figure 2 ) induces a potent Th1 response both in a murine and a human setting resulting in a superior tumor protection in the B16 mouse melanoma model. 19 Crystallographic studies of the ternary CD1d-NU-α-GalCer-TCR complex revealed that the naphthyl moiety occupies a narrow binding pocket in CD1d above the A' roof by induced fit, thereby enhancing the affinity for CD1d. The latter led us to investigate other modifications at the C-6" position. Here we describe the synthesis of a series of C-6"-carbamate and C-5"-uronamide derivatives. Figure 2 . Structures of NU-α-GalCer (4), C-6"-carbamate (5) and C-5"-uronamide derivatives (6) of α-GalCer
Results and Discussion

Chemistry
Both the C-6"-carbamates 5a-5c and the C-5"-amides 6a-6g can be accessed from the common intermediate 8, which is swiftly obtained upon treatment of the 4,6-benzylidene precursor with Cu(OTf)2 and BH3.THF. We previously started from the same intermediate for the synthesis of galacturonic acid and 6"-triazole analogues of α-GalCer. 20, 21 The primary OH group of 8 was converted into carbamates 9a and 9b upon reaction with the appropriate isocyanate, while compound 9c was obtained by treating 8 with 4-aminopyridine and 1,1'-
The synthesis of the uronamides 11a-11g commenced with the TEMPO/BAIB oxidation of the primary hydroxyl group of 8 to afford the galacturonic acid intermediate 10. 21 Successive coupling with the appropriate amine in the presence of 2-(6-chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) gave access to amides 11a-g.
Palladium-catalyzed hydrogenation furnished the desired carbamates 5a-5c and amides 6a-6e.
However, this deprotection method failed to remove the benzyl protecting groups of the sulfur-containing compound 11f, even under high pressure (50 bar), while overreduction of the naphthyl moiety was observed during hydrogenation of intermediates 9b and 11g. In case of naphthyl carbamate 9b, careful monitoring of the reaction yet allowed obtaining the final product. For the naphthyl amide compound, however, undesired reduction of the naphthyl ring was observed before all benzyl groups were removed, thereby impeding isolation of the envisaged analogue. This led us to explore alternative deprotection conditions for compounds 11f and 11g. Treatment with aluminum chloride and dimethylaniline allowed to produce the desired products 6f and 6g, albeit in low yields. 
Biological Evaluation
The biological activity of all target glycolipids was assessed by measuring IFN-γ and IL-4 serum levels after intraperitoneal injection of 5 μg in mice ( Figure 3 ). Except for 6a and 6f, the C-5"-amides are generally weaker antigens than α-GalCer with a Th1 cytokine bias, mainly originating from significantly lower IL-4 levels compared to α-GalCer.
The C-6"-carbamates clearly exhibit stronger antigenic effects than the uronamides, but their cytokine profiles resemble that of α-GalCer. It was shown that the remarkably high INF-γ release of the C-6"-carbamates (5a-c) stems from a higher APC-derived IL-12 production, compared with that of α-GalCer. 22 Notable, high IL-12 secretion was observed with 5c, largely exceeding that induced by NU-α-GalCer.
The crystal structure of the ternary mCD1d-5b-TCR complex indicates that the binding mode of 5b in the parallels that of NU-α-GalCer. In particular, its naphthylcarbamate moiety also induces a hydrophobic pocket in CD1d by displacement of Met69 (Figure 4 ), 23 indicating that the naphthyl moiety drives the observed induced fit rather than the nature of the linker, given that the length of the latter is appropriate. Probably, this extra interaction with CD1d compensates for the observed loss of the hydrogen bond between the 4"-OH group and Asn-30 of the TCR. Although the in vivo data indicate that 5b is a potent antigen, at present we have no explanation for its distinct cytokine profile compared to NU-α-GalCer.
Previously, compound 5c (PyrC-α-GalCer) was shown to be tilted towards the TCR thereby forming intimate contacts with the TCR instead of forming a third anchor inside CD1d. The carbamate moiety of 5a, on the other hand, was situated laterally above the CD1d binding group, suggesting that the smaller pyridine as well as the phenyl ring are not sufficient to induce the structural change within the A' roof of CD1d, in contrast to both 5b and NU-α-GalCer, which have the larger naphthyl ring.
Figure 4.
Crystal structure of 5b bound to CD1d, compared with that of NU-α-GalCer.
Conclusions
In summary, we have synthesized a series of C-6"-carbamate and C-5"-galacturonamide derivatives of α-GalCer from a common intermediate 8, further illustrating the highly convergent potential of the latter. Generally, the antigenic potency of the carbamates is superior to that of the uronamides, although within each series significant variations in cytokine profiles are observed depending on the substitution patterns.
The binding behavior of the naphthylcarbamate 5b in the ternary complex is strikingly similar to that of NU-α-GalCer (4). The naphthyl moiety of both analogues occupies an extra binding pocket in CD1d. Determinants for the induction of this hydrophobic pocket possibly involve the size of the aromatic group and the correct positioning of a carbonyl that acts as H-bond acceptor. By varying the carbamate substituents it may be possible to increase the interaction with either the TCR or CD1d. A notable advantage of the carbamate derivatives over their urea analogues is that the synthesis of the former is significantly shorter.
Experimental Section Chemical Synthesis
General
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were examined under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was performed on Biosolve silica gel (32 -63 µm, 60 Å). 
Procedure for the synthesis of carbamates 9a and 9b
To a solution of compound 8 (0.07 mmol) in DMF (1 mL) was added the appropriate isocyanate (0.18 mmol). After stirring overnight, the reaction mixture was evaporated to dryness under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 8/2) afforded carbamates 9a (74 %) and 9b (67 %). Hz, 6H, CH3). 
Procedure for the synthesis of carbamate 9c
To a solution of compound 8 (50 mg, 0.04 mmol) in DMF (0.5 mL) was added CDI (31 mg, 0.18 mmol). After stirring overnight, the reaction mixture was heated until 70 °C and 4-aminopyridine was added. The reaction mixture was stirred at 70 °C during 48 hours followed by evaporation to dryness under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 7/3) afforded carbamate 9c (26 mg, 33 %). 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(4-pyridinylcarbamoyl)-α-Dgalactopyranosyl)-2-(hexacosanamido)octadecane-1,3,4-triol (9c)
(
General procedure for the synthesis of amides (11a-11g)
To a solution of 10 (150 mg, 0.11 mmol) in DMF (0.3 mL) and CH2Cl2 (0. General procedure for debenzylation: (5a-5c and 6a-6e).
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(3,4-dichlorobenzyl)-α-D-galactopyranuronamidyl)-3,4-di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11d)
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(naphthalen-1-ylmethyl)-α-Dgalactopyranuronamidyl)-3,4-di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11g)
A solution of the protected amide/carbamate (0.03 mmol) in CHCl3 (0.4 mL) and EtOH (1.2 mL) was hydrogenated under atmospheric pressure in the presence of palladium black (10 mg). Upon reaction completion, the mixture was diluted with pyridine and filtered through celite. The filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After purification by column chromatography (DCM/MeOH), final compounds 5a (81%), 5b (68%), 5c (86%), 6a (86%), 6b (63%), 6c (49%), 6d (80%) and 6e (79%) were afforded as white powders. 
Procedure for debenzylation of 6f and 6g
To a solution of the protected amide (0.07 mmol) in CH2Cl2 (1 mL) was added aluminum chloride (109 mg, 0.82 mmol) and dimethylaniline (0.13 mL, 1.00 mmol). After stirring for 8 hours, the reaction mixture was quenched with a 1N solution of HCl (1.5 mL) followed by extraction with EtOAc. Next, the combined organic layers were washed with a saturated NaHCO3 solution and brine, dried over Na2SO4 and evaporated to dryness. The resulting residue was submitted to column chromatography (CH2Cl2/MeOH: 28/2), yielding amides 6f AI074952.
